Tuesday, February 25, 2025 | 01:00 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Mukesh Ambani's next disruption: Foray into genome testing with a $145 kit

The project to bring affordable personal gene-mapping to India's 1.4 bn people, will potentially create a treasure trove of biological data that can aid drug development and disease prevention

Photo: Bloomberg
Premium

Photo: Bloomberg

Saritha Rai and P R Sanjai | Bloomberg
Billionaire Mukesh Ambani’s group is getting into genetic mapping, looking to make a health care trend led by disruptive US startups like 23andMe more affordable and widespread in India’s growing consumer market.

The energy-to-ecommerce conglomerate will roll out within weeks a comprehensive 12,000-rupee ($145) genome sequencing test, according to Ramesh Hariharan, chief executive officer of Strand Life Sciences Pvt., which has developed the product. Reliance Industries Ltd., led by Asia’s richest person, acquired the Bengaluru-based firm in 2021 and now owns about 80% of it. 

The genome test, which is about 86% cheaper than other offerings available locally, can reveal

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in